https://medicaex.com/businesswire/a2-bio-identifying-solid-tumor-patients-for-possible-inclusion-in-phase-1-studies-targeting-cea-and-mesothelin-expected-to-begin-in-2023-update-at-sitc-2022/ 2022-11-07T13:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/A2-BIO-LOGO-jYUWc0.jpeg https://medicaex.com/businesswire/better-therapeutics-to-release-third-quarter-2022-financial-results-and-provide-business-update-on-november-14-2022/ 2022-11-07T13:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/Better_Tx_640x360_Logo-w9vEGG.jpeg https://medicaex.com/businesswire/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress/ 2022-11-07T12:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Full_Color_Logo_Bluebird-Logo-full-color-qI4gpd.jpeg https://medicaex.com/businesswire/kalvista-pharmaceuticals-to-present-at-upcoming-investor-conferences/ 2022-11-07T12:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Kalvista-Logo-Final-01-a6lTP2.jpeg https://medicaex.com/businesswire/global-primary-cells-market-report-2022-growing-demand-for-hla-typed-human-primary-cells-presents-opportunities-researchandmarkets-com/ 2022-11-07T12:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-ZxHpiJ.jpeg https://medicaex.com/businesswire/concert-pharmaceuticals-reports-third-quarter-2022-financial-results-2/ 2022-11-07T12:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/concert_logo_r_1976x566-wrsapd.jpeg https://medicaex.com/businesswire/repare-therapeutics-to-participate-in-two-upcoming-investor-conferences/ 2022-11-07T12:12:12+00:00 https://medicaex.com/businesswire/emocha-health-relaunches-as-scene-health-to-support-medication-adherence-for-each-individual-at-the-scene-of-their-health/ 2022-11-07T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/Scene_Logo_Black_on_Yellow-raEfLo.jpeg https://medicaex.com/businesswire/mednow-announces-senior-secured-convertible-debenture-financing-of-up-to-3000000-led-by-gravitas-securities-2/ 2022-11-07T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/0FCA406A-01A4-4533-BFC8-B5A3D5D76A36-lygAfV.jpeg https://medicaex.com/businesswire/concert-pharmaceuticals-reports-third-quarter-2022-financial-results/ 2022-11-07T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/concert_logo_r_1976x566-ZANJv6.jpeg https://medicaex.com/businesswire/glaukos-announces-participation-in-the-stephens-annual-investment-conference/ 2022-11-07T12:12:05+00:00 https://medicaex.com/businesswire/tuberculosis-testing-global-market-report-2022-global-tuberculosis-efforts-to-drive-sector-growth-researchandmarkets-com/ 2022-11-07T12:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-1Mf4kP.jpeg https://medicaex.com/businesswire/mednow-announces-senior-secured-convertible-debenture-financing-of-up-to-3000000-led-by-gravitas-securities/ 2022-11-07T12:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/0FCA406A-01A4-4533-BFC8-B5A3D5D76A36-U24k0k.jpeg https://medicaex.com/businesswire/hdt-bio-selected-to-join-blue-knight-3/ 2022-11-07T11:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/New_HDT_Logo2022_Small750x_28129-8ymfvX.jpeg https://medicaex.com/businesswire/hdt-bio-selected-to-join-blue-knight-2/ 2022-11-07T11:12:07+00:00 https://medicaex.com/wp-content/uploads/2022/11/New_HDT_Logo2022_Small750x_28129-dotkCE.jpeg https://medicaex.com/businesswire/global-enteral-feeding-formulas-market-report-2022-ease-of-use-and-low-costs-driving-adoption-researchandmarkets-com/ 2022-11-07T11:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-hdjIV4.jpeg https://medicaex.com/businesswire/revitalist-ceo-awarded-professional-service-practitioner-of-the-year-by-microdose/ 2022-11-07T11:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Revitalist_text_logo-2-iQEfpM.jpeg https://medicaex.com/businesswire/hdt-bio-selected-to-join-blue-knight/ 2022-11-07T11:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/New_HDT_Logo2022_Small750x_28129-zpbBTT.jpeg https://medicaex.com/businesswire/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research-2/ 2022-11-07T09:12:49+00:00 https://medicaex.com/wp-content/uploads/2022/11/cerveau_logo-zHDovv.jpeg https://medicaex.com/businesswire/cerveau-technologies-inc-and-lexeo-therapeutics-inc-sign-agreement-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research/ 2022-11-07T09:12:43+00:00 https://medicaex.com/wp-content/uploads/2022/11/cerveau_logo-4mCZxP.jpeg https://medicaex.com/businesswire/regimmune-to-present-results-from-the-phase-2b-study-of-rgi-2001-at-the-2022-american-society-of-hematology-annual-meeting-2/ 2022-11-07T08:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/REGiMMUNE_1400x170-IPCq82.jpeg https://medicaex.com/businesswire/regimmune-to-present-results-from-the-phase-2b-study-of-rgi-2001-at-the-2022-american-society-of-hematology-annual-meeting/ 2022-11-07T08:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/REGiMMUNE_1400x170-NkGsHB.jpeg https://medicaex.com/businesswire/sensorion-announces-us-fda-grants-rare-pediatric-disease-designation-to-otof-gt-for-the-treatment-of-otoferlin-gene-mediated-hearing-loss/ 2022-11-07T07:12:09+00:00 https://medicaex.com/businesswire/transgene-reports-business-update-and-q3-2022-financial-position-2/ 2022-11-07T07:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/Logo_Transgene-B4an0u.jpeg https://medicaex.com/businesswire/transgene-reports-business-update-and-q3-2022-financial-position/ 2022-11-07T07:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/Logo_Transgene-qvPjAy.jpeg https://medicaex.com/businesswire/innate-pharma-announces-conference-call-and-webcast-for-third-quarter-2022-business-update-2/ 2022-11-07T06:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/INNATEvertnoirDS-Jwgqoc.jpeg https://medicaex.com/businesswire/innate-pharma-announces-conference-call-and-webcast-for-third-quarter-2022-business-update/ 2022-11-07T06:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/INNATEvertnoirDS-GBagbb.jpeg https://medicaex.com/businesswire/apros-therapeutics-to-present-interim-clinical-data-from-a-phase-1-study-evaluating-apr003-at-the-2022-society-for-immunotherapy-of-cancer-sitc-annual-meeting-and-world-vaccine-immunotherapy-c-2/ 2022-11-07T05:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo_crop-Cc1MnJ.jpeg https://medicaex.com/businesswire/apros-therapeutics-to-present-interim-clinical-data-from-a-phase-1-study-evaluating-apr003-at-the-2022-society-for-immunotherapy-of-cancer-sitc-annual-meeting-and-world-vaccine-immunotherapy-c/ 2022-11-07T05:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo_crop-bcVwGw.jpeg https://medicaex.com/businesswire/recor-medical-announces-consistent-reduction-of-blood-pressure-in-pooled-analysis-of-three-clinical-trials-at-aha-2022/ 2022-11-06T16:12:07+00:00 https://medicaex.com/wp-content/uploads/2022/11/ReCor_logo-DqKSbF.jpeg https://medicaex.com/businesswire/silence-therapeutics-presents-new-analysis-from-sln360-phase-1-single-dose-study-in-high-lipoproteina-at-the-american-heart-association-aha-2022-annual-meeting-2/ 2022-11-05T15:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Silence-Logo-FINAL-rgb-RrFIiq.jpeg https://medicaex.com/businesswire/silence-therapeutics-presents-new-analysis-from-sln360-phase-1-single-dose-study-in-high-lipoproteina-at-the-american-heart-association-aha-2022-annual-meeting/ 2022-11-05T15:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Silence-Logo-FINAL-rgb-fqJBc5.jpeg https://medicaex.com/businesswire/data-support-the-use-of-krystexxa-pegloticase-injection-with-methotrexate-to-treat-uncontrolled-gout-in-people-with-mild-to-moderate-chronic-kidney-disease-2/ 2022-11-05T14:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/Horizon_Logo_Full-Color_RGB_Registered_Logo-jONXZ9.jpeg https://medicaex.com/businesswire/data-support-the-use-of-krystexxa-pegloticase-injection-with-methotrexate-to-treat-uncontrolled-gout-in-people-with-mild-to-moderate-chronic-kidney-disease/ 2022-11-05T14:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Horizon_Logo_Full-Color_RGB_Registered_Logo-g9t3o2.jpeg https://medicaex.com/businesswire/precision-biosciences-announces-grant-of-inducement-awards-under-nasdaq-listing-rule-5635c4/ 2022-11-05T00:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Precision_BioSciences_logo-YBM7M0.jpeg https://medicaex.com/businesswire/gelesis-receives-notice-of-nyse-trading-share-price-listing-rule-non-compliance-2/ 2022-11-04T22:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Gelesis_logo-Ts7Ili.jpeg https://medicaex.com/businesswire/gelesis-receives-notice-of-nyse-trading-share-price-listing-rule-non-compliance/ 2022-11-04T22:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/Gelesis_logo-6j7BXA.jpeg https://medicaex.com/businesswire/legend-biotech-announces-participation-in-upcoming-investor-conferences-2/ 2022-11-04T21:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/LEGEND_Logo_FullColor_Transparent-D5GQpj.jpeg https://medicaex.com/businesswire/iveric-bio-to-present-at-upcoming-investor-conferences-2/ 2022-11-04T21:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/Iveric_Bio_Logo-dmh1QD.jpeg https://medicaex.com/businesswire/iveric-bio-to-present-at-upcoming-investor-conferences/ 2022-11-04T21:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Iveric_Bio_Logo-8gNJSG.jpeg https://medicaex.com/businesswire/legend-biotech-announces-participation-in-upcoming-investor-conferences/ 2022-11-04T21:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/LEGEND_Logo_FullColor_Transparent-8bMQxa.jpeg https://medicaex.com/businesswire/abcellera-to-present-at-upcoming-investor-conferences-in-november-2/ 2022-11-04T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/AbCellera_Full_Colour_RGB_1-q4SyhK.jpeg https://medicaex.com/businesswire/insulet-issued-voluntary-medical-device-correction-for-omnipod-dash-personal-diabetes-manager-on-october-17-2022-3/ 2022-11-04T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/Insulet_Logo-TXAxcR.jpeg https://medicaex.com/businesswire/atara-biotherapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2/ 2022-11-04T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/Atara-Bio1_logo_300x185-1-kP4IAw.jpeg https://medicaex.com/businesswire/feinstein-institutes-bioelectronic-medicine-researchers-target-specific-vagus-nerve-fibers-for-more-precise-effective-stimulation-3/ 2022-11-04T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/News_StavrosZanos_JACC-jf7fxW.jpeg https://medicaex.com/businesswire/feinstein-institutes-bioelectronic-medicine-researchers-target-specific-vagus-nerve-fibers-for-more-precise-effective-stimulation-2/ 2022-11-04T20:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/News_StavrosZanos_JACC-BFLn5q.jpeg https://medicaex.com/businesswire/insulet-issued-voluntary-medical-device-correction-for-omnipod-dash-personal-diabetes-manager-on-october-17-2022-2/ 2022-11-04T20:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/Insulet_Logo-HFCDri.jpeg https://medicaex.com/businesswire/feinstein-institutes-bioelectronic-medicine-researchers-target-specific-vagus-nerve-fibers-for-more-precise-effective-stimulation/ 2022-11-04T20:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/News_StavrosZanos_JACC-BqjL8x.jpeg https://medicaex.com/businesswire/abcellera-to-present-at-upcoming-investor-conferences-in-november/ 2022-11-04T20:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/AbCellera_Full_Colour_RGB_1-0YlgWV.jpeg https://medicaex.com/businesswire/insulet-issued-voluntary-medical-device-correction-for-omnipod-dash-personal-diabetes-manager-on-october-17-2022/ 2022-11-04T20:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Insulet_Logo-Mj1KlE.jpeg https://medicaex.com/businesswire/atara-biotherapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/ 2022-11-04T20:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Atara-Bio1_logo_300x185-1-01yKHG.jpeg https://medicaex.com/businesswire/europe-anti-infective-agents-market-report-2022-increasing-government-support-for-research-activities-and-clinical-trials-drives-sector-growth-researchandmarkets-com-2/ 2022-11-04T18:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-WSOgYY.jpeg https://medicaex.com/businesswire/global-copd-asthma-diagnostic-and-monitoring-devices-market-report-2022-portability-of-the-drug-delivery-devices-driving-growth-researchandmarkets-com-2/ 2022-11-04T18:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-LxV7od.jpeg https://medicaex.com/businesswire/global-copd-asthma-diagnostic-and-monitoring-devices-market-report-2022-portability-of-the-drug-delivery-devices-driving-growth-researchandmarkets-com/ 2022-11-04T18:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-swGITv.jpeg https://medicaex.com/businesswire/europe-anti-infective-agents-market-report-2022-increasing-government-support-for-research-activities-and-clinical-trials-drives-sector-growth-researchandmarkets-com/ 2022-11-04T18:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-cteYiK.jpeg https://medicaex.com/businesswire/global-local-anesthesia-drugs-market-report-2022-increasing-number-of-surgeries-bolstering-sector-growth-researchandmarkets-com/ 2022-11-04T18:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-rsbreC.jpeg https://medicaex.com/businesswire/global-bcg-tuberculosis-vaccine-market-report-2022-high-prevalence-and-incidence-rates-of-tuberculosis-worldwide-driving-growth-researchandmarkets-com/ 2022-11-04T18:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-jEU0WU.jpeg https://medicaex.com/businesswire/global-respiratory-disease-vaccine-market-report-2022-increasing-rd-expenditure-by-leading-companies-presents-opportunities-researchandmarkets-com-2/ 2022-11-04T17:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-57tUpr.jpeg https://medicaex.com/businesswire/global-bioreactors-market-report-2022-rapid-growth-of-the-biopharmaceuticals-and-biologics-industry-driving-sector-researchandmarkets-com-2/ 2022-11-04T17:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-c2g418.jpeg https://medicaex.com/businesswire/global-respiratory-disease-vaccine-market-report-2022-increasing-rd-expenditure-by-leading-companies-presents-opportunities-researchandmarkets-com/ 2022-11-04T17:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-HldPNt.jpeg https://medicaex.com/businesswire/global-osimertinib-drugs-market-report-2022-relatively-low-risk-of-side-effects-compared-to-other-drugs-driving-adoption-researchandmarkets-com/ 2022-11-04T17:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-adjbjm.jpeg https://medicaex.com/businesswire/global-bioreactors-market-report-2022-rapid-growth-of-the-biopharmaceuticals-and-biologics-industry-driving-sector-researchandmarkets-com/ 2022-11-04T17:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-dVD7SO.jpeg https://medicaex.com/businesswire/global-topical-drug-delivery-market-report-2022-delivery-of-biologics-through-the-transdermal-route-presents-opportunities-for-innovation-researchandmarkets-com/ 2022-11-04T17:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-leImcc.jpeg https://medicaex.com/businesswire/global-clinical-trials-outsourcing-market-report-2022-lower-costs-shorter-turnaround-times-and-better-results-drive-sector-growth-researchandmarkets-com-2/ 2022-11-04T16:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-KJng5N.jpeg https://medicaex.com/businesswire/preclinical-cro-global-market-report-2022-rising-number-of-drugs-in-preclinical-trials-driving-growth-researchandmarkets-com/ 2022-11-04T16:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-joTuR7.jpeg https://medicaex.com/businesswire/compounding-pharmacies-global-market-report-2022-featuring-avella-specialty-pharmacy-fagron-pharmedium-b-braun-melsungen-more-researchandmarkets-com/ 2022-11-04T16:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-fvbyug.jpeg https://medicaex.com/businesswire/global-clinical-trials-outsourcing-market-report-2022-lower-costs-shorter-turnaround-times-and-better-results-drive-sector-growth-researchandmarkets-com/ 2022-11-04T16:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-kRBjgO.jpeg https://medicaex.com/businesswire/global-rat-model-market-report-2022-growing-production-of-monoclonal-antibodies-gives-boost-to-sector-researchandmarkets-com-2/ 2022-11-04T15:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-lv7lbw.jpeg https://medicaex.com/businesswire/north-america-medical-robots-market-report-2022-evolution-of-nanorobots-for-cancer-treatment-presents-opportunities-researchandmarkets-com-3/ 2022-11-04T15:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-76yaBu.jpeg https://medicaex.com/businesswire/asia-pacific-proton-therapy-market-report-2022-development-of-flash-radiation-presents-opportunities-researchandmarkets-com-3/ 2022-11-04T15:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-ffPoDu.jpeg https://medicaex.com/businesswire/landmark-empa-kidney-trial-showed-significant-benefit-of-jardiance-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease-2/ 2022-11-04T15:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/EMPA_Kidney_Trial_Full_Data_Infographic_v16-VSKDmu.jpeg https://medicaex.com/businesswire/asia-pacific-proton-therapy-market-report-2022-development-of-flash-radiation-presents-opportunities-researchandmarkets-com-2/ 2022-11-04T15:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-GnCXUF.jpeg https://medicaex.com/businesswire/30-finalists-announced-for-zayed-sustainability-prize-2023/ 2022-11-04T15:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/Images_of_the_2023_Zayed_Sustainability_Prize_Jury_28Photo_AETOSWire29-1fShod.jpeg https://medicaex.com/businesswire/north-america-medical-robots-market-report-2022-evolution-of-nanorobots-for-cancer-treatment-presents-opportunities-researchandmarkets-com-2/ 2022-11-04T15:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-A8aJU4.jpeg https://medicaex.com/businesswire/north-america-medical-robots-market-report-2022-evolution-of-nanorobots-for-cancer-treatment-presents-opportunities-researchandmarkets-com/ 2022-11-04T15:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-r5q3iv.jpeg https://medicaex.com/businesswire/asia-pacific-proton-therapy-market-report-2022-development-of-flash-radiation-presents-opportunities-researchandmarkets-com/ 2022-11-04T15:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-2XCYvP.jpeg https://medicaex.com/businesswire/landmark-empa-kidney-trial-showed-significant-benefit-of-jardiance-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease/ 2022-11-04T15:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/EMPA_Kidney_Trial_Full_Data_Infographic_v16-hw3bXw.jpeg https://medicaex.com/businesswire/global-rat-model-market-report-2022-growing-production-of-monoclonal-antibodies-gives-boost-to-sector-researchandmarkets-com/ 2022-11-04T15:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-jhpaAQ.jpeg https://medicaex.com/businesswire/women-in-psychedelics-announces-atai-as-platinum-sponsors/ 2022-11-04T14:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/WIPN-TTcbmd.jpeg https://medicaex.com/businesswire/flatiron-health-announces-research-to-be-presented-at-international-society-for-pharmacoeconomics-and-outcomes-research-europe-2022-annual-meeting-3/ 2022-11-04T14:12:13+00:00 https://medicaex.com/businesswire/maze-therapeutics-presents-preclinical-data-highlighting-potential-of-apol1-inhibitor-program-as-a-treatment-for-chronic-kidney-disease-2/ 2022-11-04T14:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/lol-s8SYM5.jpeg https://medicaex.com/businesswire/flatiron-health-announces-research-to-be-presented-at-international-society-for-pharmacoeconomics-and-outcomes-research-europe-2022-annual-meeting-2/ 2022-11-04T14:12:10+00:00 https://medicaex.com/businesswire/global-dialysis-market-report-2022-preference-for-dialysis-over-transplants-driving-sector-growth-researchandmarkets-com/ 2022-11-04T14:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-QUekIZ.jpeg https://medicaex.com/businesswire/acorda-therapeutics-announces-adjournment-of-special-meeting-of-stockholders/ 2022-11-04T14:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/Acorda_Logo-Color_Print-rCWlCE.jpeg https://medicaex.com/businesswire/maze-therapeutics-presents-preclinical-data-highlighting-potential-of-apol1-inhibitor-program-as-a-treatment-for-chronic-kidney-disease/ 2022-11-04T14:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/lol-g11Up6.jpeg https://medicaex.com/businesswire/flatiron-health-announces-research-to-be-presented-at-international-society-for-pharmacoeconomics-and-outcomes-research-europe-2022-annual-meeting/ 2022-11-04T14:12:04+00:00 https://medicaex.com/businesswire/timelymd-ceo-luke-hejl-named-entrepreneur-of-excellence/ 2022-11-04T14:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/TimelyMD_CEO_Luke_Hejl_Landscape-4hdqz4.jpeg https://medicaex.com/businesswire/outset-medical-secures-up-to-300-million-in-debt-financing-3/ 2022-11-04T13:12:19+00:00 https://medicaex.com/wp-content/uploads/2022/11/Outset-ID-OrangeGrey-ilU8lf.jpeg https://medicaex.com/businesswire/omeros-corporation-to-announce-third-quarter-financial-results-on-november-9-2022-2/ 2022-11-04T13:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/Omeros_Logo_RGB_with_R.2014-r0fTxd.jpeg https://medicaex.com/businesswire/naturalshrimp-attending-world-food-championships-in-dallas/ 2022-11-04T13:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/SHMP_Logo_6-11-2021-XyDylp.jpeg https://medicaex.com/businesswire/exactech-announces-fda-510k-clearance-of-the-triverse-primary-knee-replacement-system-2/ 2022-11-04T13:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/ExactechLogo_use_on_white_bkgd-wTN1IR.jpeg https://medicaex.com/businesswire/vistagen-to-report-fiscal-year-2023-second-quarter-financial-results-on-november-10-2022-2/ 2022-11-04T13:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/Vistagen_Primary-Logo_Blue-gumCAD.jpeg https://medicaex.com/businesswire/yes-hearing-the-leader-of-in-home-hearing-services-closes-10m-series-a-to-expand-access-to-affordable-and-professional-hearing-care-2/ 2022-11-04T13:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/Yes_Logo-HfWJAp.jpeg https://medicaex.com/businesswire/outset-medical-secures-up-to-300-million-in-debt-financing-2/ 2022-11-04T13:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/Outset-ID-OrangeGrey-fgM5Tv.jpeg https://medicaex.com/businesswire/outset-medical-secures-up-to-300-million-in-debt-financing/ 2022-11-04T13:12:14+00:00 https://medicaex.com/wp-content/uploads/2022/11/Outset-ID-OrangeGrey-mI4o1s.jpeg https://medicaex.com/businesswire/exactech-announces-fda-510k-clearance-of-the-triverse-primary-knee-replacement-system/ 2022-11-04T13:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/ExactechLogo_use_on_white_bkgd-woKceh.jpeg https://medicaex.com/businesswire/new-approach-to-clinical-trial-design-helps-medical-devices-better-meet-patient-needs-and-priorities/ 2022-11-04T13:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-1-4gbrlY.jpeg https://medicaex.com/businesswire/ansell-adopts-exabeam-fusion-for-threat-detection-investigation-and-response/ 2022-11-04T13:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Exabeam_logo-wgWcDh.jpeg https://medicaex.com/businesswire/omeros-corporation-to-announce-third-quarter-financial-results-on-november-9-2022/ 2022-11-04T13:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/Omeros_Logo_RGB_with_R.2014-iyGYkc.jpeg https://medicaex.com/businesswire/vistagen-to-report-fiscal-year-2023-second-quarter-financial-results-on-november-10-2022/ 2022-11-04T13:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/Vistagen_Primary-Logo_Blue-XscWWx.jpeg https://medicaex.com/businesswire/yes-hearing-the-leader-of-in-home-hearing-services-closes-10m-series-a-to-expand-access-to-affordable-and-professional-hearing-care/ 2022-11-04T13:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Yes_Logo-GZzfIR.jpeg https://medicaex.com/businesswire/included-health-appoints-michael-bender-to-board-of-directors/ 2022-11-04T13:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Included_Logo_FullColor_Screen_28129-cxtwTs.jpeg https://medicaex.com/businesswire/nanopharmaceuticals-global-market-report-2022-huge-market-potential-in-pharmaceutical-companies-for-development-of-effective-therapeutics-researchandmarkets-com-2/ 2022-11-04T12:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-yVbuAK.jpeg https://medicaex.com/businesswire/ocelot-bio-presents-phase-1-data-highlighting-activity-and-safety-of-oce-205-at-aasld-the-liver-meeting-2/ 2022-11-04T12:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/OcelotBio_FullColor_rgb_2022JUL08-Dx80ot.jpeg https://medicaex.com/businesswire/asher-bio-presents-new-data-demonstrating-preclinical-proof-of-concept-for-ab359-a-highly-selective-cd8-targeted-il-2-therapy-for-chronic-hepatitis-b-hbv-at-aasld-2022-2/ 2022-11-04T12:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/AsherBio-logo-ADHYTM.jpeg https://medicaex.com/businesswire/revance-announces-two-publications-in-the-aesthetic-surgery-journal-that-advance-glabellar-line-injection-technique-and-assessment/ 2022-11-04T12:12:16+00:00 https://medicaex.com/businesswire/vertex-announces-partnership-with-basketball-hall-of-famer-alonzo-mourning-to-raise-awareness-of-apol1-mediated-kidney-disease-amkd/ 2022-11-04T12:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/Vertex_Logo_colorRGB-KQeaUa.jpeg https://medicaex.com/businesswire/applied-uv-to-host-third-quarter-2022-conference-call-on-november-15-2022-2/ 2022-11-04T12:12:13+00:00 https://medicaex.com/businesswire/zephyr-ai-and-medstar-health-embark-on-an-ambitious-partnership-to-enhance-predictive-analytic-capabilities-for-chronic-disease/ 2022-11-04T12:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/86B7464A-884F-4464-A9D8-8F7A1D3DAF8C-gFwVa0.jpeg https://medicaex.com/businesswire/viz-ai-launches-ai-powered-viztm-cardio-suite-2/ 2022-11-04T12:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Viz_Cardio_Suite_11-22-XhEP3J.jpeg https://medicaex.com/businesswire/global-medical-market-tracker-2022-forecasts-for-semiconductors-used-in-medical-applications-including-designs-used-in-over-the-counter-consumer-devices-therapeutic-and-imaging-equipment-researcha/ 2022-11-04T12:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-V9lXQJ.jpeg https://medicaex.com/businesswire/viz-ai-launches-ai-powered-viztm-cardio-suite/ 2022-11-04T12:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Viz_Cardio_Suite_11-22-msJvAS.jpeg https://medicaex.com/businesswire/cardiac-insight-comments-on-cms-announcement-of-national-payment-rates-for-long-term-continuous-ecg-lt-ecg-monitoring-in-2023/ 2022-11-04T12:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Cardiac_Insight_logo_4c_28129-gNpOwY.jpeg https://medicaex.com/businesswire/applied-uv-to-host-third-quarter-2022-conference-call-on-november-15-2022/ 2022-11-04T12:12:11+00:00 https://medicaex.com/businesswire/cerus-corporation-to-participate-in-upcoming-investor-conferences/ 2022-11-04T12:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/cerus_210x60-2aAZoh.jpeg https://medicaex.com/businesswire/walgreens-teams-up-with-its-health-corners-and-clinic-partners-to-expand-access-to-complimentary-diabetes-services-during-diabetes-awareness-month-3/ 2022-11-04T12:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/Walgreens_pharmacist_person_with_diabetes-h78FOB.jpeg https://medicaex.com/businesswire/walgreens-teams-up-with-its-health-corners-and-clinic-partners-to-expand-access-to-complimentary-diabetes-services-during-diabetes-awareness-month-2/ 2022-11-04T12:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/Walgreens_pharmacist_person_with_diabetes-gj2QHQ.jpeg https://medicaex.com/businesswire/walgreens-teams-up-with-its-health-corners-and-clinic-partners-to-expand-access-to-complimentary-diabetes-services-during-diabetes-awareness-month/ 2022-11-04T12:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/Walgreens_pharmacist_person_with_diabetes-BtQhAY.jpeg https://medicaex.com/businesswire/asher-bio-presents-new-data-demonstrating-preclinical-proof-of-concept-for-ab359-a-highly-selective-cd8-targeted-il-2-therapy-for-chronic-hepatitis-b-hbv-at-aasld-2022/ 2022-11-04T12:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/AsherBio-logo-GfTcFX.jpeg https://medicaex.com/businesswire/nanopharmaceuticals-global-market-report-2022-huge-market-potential-in-pharmaceutical-companies-for-development-of-effective-therapeutics-researchandmarkets-com/ 2022-11-04T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-5eYOsD.jpeg https://medicaex.com/businesswire/ocelot-bio-presents-phase-1-data-highlighting-activity-and-safety-of-oce-205-at-aasld-the-liver-meeting/ 2022-11-04T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/OcelotBio_FullColor_rgb_2022JUL08-M2nbrR.jpeg https://medicaex.com/businesswire/the-worldwide-paracetamol-iv-industry-is-expected-to-reach-1-2-billion-by-2027-enhanced-usage-of-acetaminophen-to-reduce-the-dependence-on-opioids-for-pain-management-is-driving-growth-researchand/ 2022-11-04T12:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-4IF1JQ.jpeg https://medicaex.com/businesswire/beigene-to-present-at-upcoming-investor-conferences-2/ 2022-11-04T11:12:14+00:00 https://medicaex.com/wp-content/uploads/2022/11/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB-d84FQN.jpeg https://medicaex.com/businesswire/pfizer-and-biontech-announce-updated-clinical-data-for-omicron-ba-4-ba-5-adapted-bivalent-booster-demonstrating-substantially-higher-immune-response-in-adults-compared-to-the-original-covid-19-vacci-2/ 2022-11-04T11:12:14+00:00 https://medicaex.com/wp-content/uploads/2022/11/Pfizer_Logo_Color_RGB_APPROVED-BxRjDm.jpeg https://medicaex.com/businesswire/bicycle-therapeutics-to-participate-in-upcoming-investor-conferences-2/ 2022-11-04T11:12:13+00:00 https://medicaex.com/businesswire/elucids-next-generation-plaque-analysis-and-ffrct-technology-to-be-featured-on-2022-aha-scientific-sessions-program-3/ 2022-11-04T11:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Elucid-Logo-CMYK_copy-K6PeUd.jpeg https://medicaex.com/businesswire/aphenas-three-year-20m-tennessee-expansion-now-complete-3/ 2022-11-04T11:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Aphena_Cookeville_Tennessee-YQiX1s.jpeg https://medicaex.com/businesswire/unitedhealth-group-board-authorizes-payment-of-quarterly-dividend/ 2022-11-04T11:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/UHG_Logo_2-nSbK60.jpeg https://medicaex.com/businesswire/elucids-next-generation-plaque-analysis-and-ffrct-technology-to-be-featured-on-2022-aha-scientific-sessions-program-2/ 2022-11-04T11:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/Elucid-Logo-CMYK_copy-zvLNkT.jpeg https://medicaex.com/businesswire/caredx-to-participate-in-upcoming-investor-conferences/ 2022-11-04T11:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/CareDx_Logo-xfWwxY.jpeg https://medicaex.com/businesswire/elucids-next-generation-plaque-analysis-and-ffrct-technology-to-be-featured-on-2022-aha-scientific-sessions-program/ 2022-11-04T11:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/Elucid-Logo-CMYK_copy-fxmKsi.jpeg https://medicaex.com/businesswire/aphenas-three-year-20m-tennessee-expansion-now-complete-2/ 2022-11-04T11:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/Aphena_Cookeville_Tennessee-QOkzlh.jpeg https://medicaex.com/businesswire/bicycle-therapeutics-to-participate-in-upcoming-investor-conferences/ 2022-11-04T11:12:05+00:00 https://medicaex.com/businesswire/aphenas-three-year-20m-tennessee-expansion-now-complete/ 2022-11-04T11:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/Aphena_Cookeville_Tennessee-jyOJlv.jpeg https://medicaex.com/businesswire/beigene-to-present-at-upcoming-investor-conferences/ 2022-11-04T11:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB-DBoB97.jpeg https://medicaex.com/businesswire/pfizer-and-biontech-announce-updated-clinical-data-for-omicron-ba-4-ba-5-adapted-bivalent-booster-demonstrating-substantially-higher-immune-response-in-adults-compared-to-the-original-covid-19-vaccine/ 2022-11-04T11:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/Pfizer_Logo_Color_RGB_APPROVED-0hFJDm.jpeg https://medicaex.com/businesswire/immunogen-reports-recent-progress-and-third-quarter-2022-financial-results/ 2022-11-04T11:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/imgnlogo-WpPKxw.jpeg https://medicaex.com/businesswire/amneal-reports-third-quarter-2022-financial-results-2/ 2022-11-04T10:12:18+00:00 https://medicaex.com/wp-content/uploads/2022/11/amneallogo-uUN7va.jpeg https://medicaex.com/businesswire/amneal-reports-third-quarter-2022-financial-results/ 2022-11-04T10:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/amneallogo-JKEyEO.jpeg https://medicaex.com/businesswire/headspace-health-introduces-unified-mental-health-and-wellbeing-experience-for-employers-and-employees-3/ 2022-11-04T09:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/UMD-Businesswire_3_28229-Jy9FVs.jpeg https://medicaex.com/businesswire/future-planet-capital-backs-roslin-techs-momentum-with-further-investment/ 2022-11-04T09:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo_Future_Planet_Captial_2800229-IYR6xp.jpeg https://medicaex.com/businesswire/headspace-health-introduces-unified-mental-health-and-wellbeing-experience-for-employers-and-employees-2/ 2022-11-04T09:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/UMD-Businesswire_3_28229-UaJXrv.jpeg https://medicaex.com/businesswire/headspace-health-introduces-unified-mental-health-and-wellbeing-experience-for-employers-and-employees/ 2022-11-04T09:12:02+00:00 https://medicaex.com/wp-content/uploads/2022/11/UMD-Businesswire_3_28229-DjM1yc.jpeg https://medicaex.com/businesswire/beckley-psytech-to-attend-and-present-at-the-jefferies-london-healthcare-conference-november-15-17-2022-2/ 2022-11-04T07:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/Beckley_Psytech_Logo_high_res-nkBu7I.jpeg https://medicaex.com/businesswire/beckley-psytech-to-attend-and-present-at-the-jefferies-london-healthcare-conference-november-15-17-2022/ 2022-11-04T07:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Beckley_Psytech_Logo_high_res-I36kIf.jpeg https://medicaex.com/businesswire/innate-pharma-to-present-results-from-a-preliminary-analysis-of-the-tellomak-phase-2-trial-in-patients-with-advanced-sezary-syndrome-and-anket-platform-at-ash-2022-2/ 2022-11-04T06:13:02+00:00 https://medicaex.com/wp-content/uploads/2022/11/INNATEvertnoirDS-3XAJvV.jpeg https://medicaex.com/businesswire/benevolentai-to-present-at-jefferies-investor-conference-in-november-2/ 2022-11-04T06:12:58+00:00 https://medicaex.com/businesswire/innate-pharma-to-present-results-from-a-preliminary-analysis-of-the-tellomak-phase-2-trial-in-patients-with-advanced-sezary-syndrome-and-anket-platform-at-ash-2022/ 2022-11-04T06:12:52+00:00 https://medicaex.com/wp-content/uploads/2022/11/INNATEvertnoirDS-nfFdMm.jpeg https://medicaex.com/businesswire/benevolentai-to-present-at-jefferies-investor-conference-in-november/ 2022-11-04T06:12:52+00:00 https://medicaex.com/businesswire/sinovac-varicella-vaccine-prequalified-by-who-2/ 2022-11-04T02:12:14+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-tu4zH3.jpeg https://medicaex.com/businesswire/sinovac-varicella-vaccine-prequalified-by-who/ 2022-11-04T02:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-TtpYDN.jpeg https://medicaex.com/businesswire/inogen-to-present-at-upcoming-investor-conferences-in-november-2022-2/ 2022-11-04T01:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Inogen_Logo_300_DPI-q1ZDa8.jpeg https://medicaex.com/businesswire/inogen-to-present-at-upcoming-investor-conferences-in-november-2022/ 2022-11-04T01:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/Inogen_Logo_300_DPI-yvzE9R.jpeg https://medicaex.com/businesswire/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline-2/ 2022-11-04T00:12:14+00:00 https://medicaex.com/wp-content/uploads/2022/11/Cimeio_logo-eZFYVN.jpeg https://medicaex.com/businesswire/cimeio-therapeutics-announces-acceptance-of-ash-abstracts-detailing-pipeline/ 2022-11-04T00:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Cimeio_logo-tZbCNr.jpeg https://medicaex.com/businesswire/ahf-celebrates-30-years-of-340b/ 2022-11-03T23:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Let340B-sNK6db.jpeg https://medicaex.com/businesswire/iveric-bio-announces-submission-of-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/ 2022-11-03T23:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/Iveric_Bio_Logo-G4hkSv.jpeg https://medicaex.com/businesswire/alpine-immune-sciences-presents-update-of-alpn-303-phase-1-ruby-1-clinical-data-at-the-american-society-of-nephrology-kidney-week-2022-meeting-2/ 2022-11-03T21:12:17+00:00 https://medicaex.com/wp-content/uploads/2022/11/AIS-Logo-P4eBR4.jpeg https://medicaex.com/businesswire/merrimack-reports-third-quarter-2022-financial-results-2/ 2022-11-03T21:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/MACK_Logo_12.2.19-ZNEDAu.jpeg https://medicaex.com/businesswire/bostongene-announces-abstract-presentation-at-the-association-for-molecular-pathology-2022-annual-meeting/ 2022-11-03T21:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/bostongene-logo-O7knq1.jpeg https://medicaex.com/businesswire/merrimack-reports-third-quarter-2022-financial-results/ 2022-11-03T21:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/MACK_Logo_12.2.19-9HQWBj.jpeg https://medicaex.com/businesswire/rite-aid-announces-cash-tender-offer-and-consent-solicitation-for-up-to-200000000-aggregate-purchase-price-of-7-500-senior-secured-notes-due-2025/ 2022-11-03T21:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/RAD-Logo-PMS-utGUvZ.jpeg https://medicaex.com/businesswire/alpine-immune-sciences-presents-update-of-alpn-303-phase-1-ruby-1-clinical-data-at-the-american-society-of-nephrology-kidney-week-2022-meeting/ 2022-11-03T21:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/AIS-Logo-cPkISC.jpeg https://medicaex.com/businesswire/nuvation-bio-reports-third-quarter-2022-financial-results-and-provides-business-update-2/ 2022-11-03T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/NUVB_Logo-YJuFJg.jpeg https://medicaex.com/businesswire/amylyx-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-november-10-2022-2/ 2022-11-03T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/13268_Amylyx_logo_notagline-Color-eSvGtZ.jpeg https://medicaex.com/businesswire/prothena-reports-third-quarter-2022-financial-results-and-business-highlights-2/ 2022-11-03T20:12:20+00:00 https://medicaex.com/wp-content/uploads/2022/11/Prothena_RGB_fullcolor-4qRnAL.jpeg https://medicaex.com/businesswire/verastem-oncology-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progress-2/ 2022-11-03T20:12:20+00:00 https://medicaex.com/businesswire/guardant-health-reports-third-quarter-2022-financial-results-4/ 2022-11-03T20:12:20+00:00 https://medicaex.com/businesswire/nanthealth-reports-2022-third-quarter-financial-results/ 2022-11-03T20:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/NantHealth-RGB40640-xOf8xX.jpeg https://medicaex.com/businesswire/caredx-reports-third-quarter-2022-results/ 2022-11-03T20:12:16+00:00 https://medicaex.com/wp-content/uploads/2022/11/CareDx_Logo-8tZfWB.jpeg https://medicaex.com/businesswire/schrodinger-reports-third-quarter-2022-financial-results/ 2022-11-03T20:12:16+00:00 https://medicaex.com/businesswire/agilon-health-reports-third-quarter-2022-results/ 2022-11-03T20:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/Agilon_Logo_640x360-D1CLMI.jpeg https://medicaex.com/businesswire/myomo-to-report-third-quarter-financial-results-on-november-10-2022-2/ 2022-11-03T20:12:15+00:00 https://medicaex.com/wp-content/uploads/2022/11/Myomo_tag_28529-k3M9q3.jpeg https://medicaex.com/businesswire/allscripts-announces-third-quarter-of-2022-results-2/ 2022-11-03T20:12:13+00:00 https://medicaex.com/wp-content/uploads/2022/11/Allscripts-Logo-FwmSfX.jpeg https://medicaex.com/businesswire/atec-reports-third-quarter-2022-financial-results/ 2022-11-03T20:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/informed_logo_on_white-MZX63G.jpeg https://medicaex.com/businesswire/cutera-announces-third-quarter-2022-financial-results/ 2022-11-03T20:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/Cutera_Logo-IMRxgb.jpeg https://medicaex.com/businesswire/myomo-to-report-third-quarter-financial-results-on-november-10-2022/ 2022-11-03T20:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/Myomo_tag_28529-MIDY1B.jpeg https://medicaex.com/businesswire/guardant-health-reports-third-quarter-2022-financial-results-3/ 2022-11-03T20:12:12+00:00 https://medicaex.com/businesswire/cerus-corporation-announces-third-quarter-financial-results/ 2022-11-03T20:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/cerus_210x60-Br1Wjn.jpeg https://medicaex.com/businesswire/guardant-health-reports-third-quarter-2022-financial-results-2/ 2022-11-03T20:12:08+00:00 https://medicaex.com/businesswire/allscripts-announces-third-quarter-of-2022-results/ 2022-11-03T20:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/Allscripts-Logo-veWIOL.jpeg https://medicaex.com/businesswire/amylyx-pharmaceuticals-to-report-third-quarter-2022-financial-results-on-november-10-2022/ 2022-11-03T20:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/13268_Amylyx_logo_notagline-Color-YZiPpv.jpeg https://medicaex.com/businesswire/prothena-reports-third-quarter-2022-financial-results-and-business-highlights/ 2022-11-03T20:12:05+00:00 https://medicaex.com/wp-content/uploads/2022/11/Prothena_RGB_fullcolor-ma2MI0.jpeg https://medicaex.com/businesswire/verastem-oncology-reports-third-quarter-2022-financial-results-and-highlights-recent-company-progress/ 2022-11-03T20:12:05+00:00 https://medicaex.com/businesswire/guardant-health-reports-third-quarter-2022-financial-results/ 2022-11-03T20:12:05+00:00 https://medicaex.com/businesswire/nuvation-bio-reports-third-quarter-2022-financial-results-and-provides-business-update/ 2022-11-03T20:12:04+00:00 https://medicaex.com/wp-content/uploads/2022/11/NUVB_Logo-uEeUhh.jpeg https://medicaex.com/businesswire/longhorn-vaccines-diagnostics-recognized-as-biotech-breakthroughs-diagnostics-company-of-the-year-3/ 2022-11-03T19:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/LonghornLogo-WYJruO.jpeg https://medicaex.com/businesswire/new-report-shows-life-sciences-as-a-major-economic-and-innovation-engine-for-georgia-2/ 2022-11-03T19:12:10+00:00 https://medicaex.com/wp-content/uploads/2022/11/CGHI_Logo-2_RGB-B_300dpi-3OQYC6.jpeg https://medicaex.com/businesswire/massachusettss-general-hospital-study-demonstrates-prevencios-ai-driven-hart-cve-blood-test-highly-accurate-for-predicting-major-cardiac-events-in-patients-with-chronic-kidney-diseas/ 2022-11-03T19:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/PrevencioLogo-R8oXQg.jpeg https://medicaex.com/businesswire/new-report-shows-life-sciences-as-a-major-economic-and-innovation-engine-for-georgia/ 2022-11-03T19:12:08+00:00 https://medicaex.com/wp-content/uploads/2022/11/CGHI_Logo-2_RGB-B_300dpi-sO0ao6.jpeg https://medicaex.com/businesswire/longhorn-vaccines-diagnostics-recognized-as-biotech-breakthroughs-diagnostics-company-of-the-year-2/ 2022-11-03T19:12:06+00:00 https://medicaex.com/wp-content/uploads/2022/11/LonghornLogo-UUrOhM.jpeg https://medicaex.com/businesswire/longhorn-vaccines-diagnostics-recognized-as-biotech-breakthroughs-diagnostics-company-of-the-year/ 2022-11-03T19:12:03+00:00 https://medicaex.com/wp-content/uploads/2022/11/LonghornLogo-wEuMtj.jpeg https://medicaex.com/businesswire/presentations-on-ropeginterferon-alfa-2b-during-ash-annual-meeting-highlight-momentum-in-the-care-of-polycythemia-vera-2/ 2022-11-03T18:12:12+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-pharma-essentia-keYu6L.jpeg https://medicaex.com/businesswire/twist-bioscience-to-report-fiscal-2022-fourth-quarter-and-full-year-financial-results-on-friday-november-18-2022-2/ 2022-11-03T18:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Twist_Bioscience_Logo-Pk89aG.jpeg https://medicaex.com/businesswire/saudi-arabia-diagnostic-imaging-x-ray-imaging-solutions-ultrasound-mri-ct-nuclear-imaging-solutions-mammography-markets-analysis-competition-forecast-opportunities-2017-2022-202-3/ 2022-11-03T18:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-I7RSr3.jpeg https://medicaex.com/businesswire/novadip-biosciences-raises-additional-eur-40-million-bringing-total-company-funding-to-eur-88-million-3/ 2022-11-03T18:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/191016_Novadip_Logo_horizontal_RGB_Large-5n2Utn.jpeg https://medicaex.com/businesswire/avencell-to-present-new-data-from-lead-universal-car-t-cell-therapy-program-at-64th-american-society-of-hematology-annual-meeting-and-exposition-2/ 2022-11-03T18:12:11+00:00 https://medicaex.com/wp-content/uploads/2022/11/Avencell-HighRes_colour-1PqqSB.jpeg https://medicaex.com/businesswire/saudi-arabia-diagnostic-imaging-x-ray-imaging-solutions-ultrasound-mri-ct-nuclear-imaging-solutions-mammography-markets-analysis-competition-forecast-opportunities-2017-2022-202-2/ 2022-11-03T18:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-yCeoIk.jpeg https://medicaex.com/businesswire/global-digital-diabetes-management-market-report-to-2027-increasing-diabetes-related-health-expenditure-presents-opportunities-researchandmarkets-com-2/ 2022-11-03T18:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/logo-bYreCX.jpeg https://medicaex.com/businesswire/swap-health-launches-out-of-stealth-with-investment-from-25m-health-partnership-with-university-of-florida/ 2022-11-03T18:12:09+00:00 https://medicaex.com/wp-content/uploads/2022/11/Swap-V5hOY7.jpeg